Evidence map›Paper›PMID 26395556›Full record

ArticleEuropean journal of human genetics : EJHG2016

9q33.3q34.11 microdeletion: new contiguous gene syndrome encompassing STXBP1, LMX1B and ENG genes assessed using reverse phenotyping.

Sophie Nambot, Alice Masurel, Salima El Chehadeh, Anne-Laure Mosca-Boidron, Christel Thauvin-Robinet, Mathilde Lefebvre, Nathalie Marle, Julien Thevenon, Stéphanie Perez-Martin, Véronique Dulieu and 19 more

Abstract readCase Reports
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sophie NambotCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.
Alice MasurelCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.
Salima El ChehadehCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.
Anne-Laure Mosca-BoidronLaboratoire de Cytogénétique, Plateau Technique de Biologie, CHU, Dijon, France.
Christel Thauvin-RobinetCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.
Mathilde LefebvreCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.
Nathalie MarleLaboratoire de Cytogénétique, Plateau Technique de Biologie, CHU, Dijon, France.
Julien ThevenonCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.ORCID 0000-0001-9271-3961
Stéphanie Perez-MartinService de Pédiatrie 1, Hôpital d'Enfants, CHU, Dijon, France.
Véronique DulieuService de Soins de Suite et de Réeducation Pédiatrique, Pôle Réeducation Réadaptation, CHU, Dijon, France.
Frédéric HuetService de Pédiatrie 1, Hôpital d'Enfants, CHU, Dijon, France.
Ghislaine PlessisCentre de Compétence des Anomalies du Développement, CHU, Caen, France.
Joris AndrieuxLaboratoire de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU, Lille, France.
Pierre-Simon JoukCentre de Référence "Anomalies du Développement et Syndromes Malformatifs", Centre Est, CHU, Grenoble, France.
Gipsy Billy-LopezCentre de Référence "Anomalies du Développement et Syndromes Malformatifs", Centre Est, CHU, Grenoble, France.
Charles CouttonLaboratoire de Génétique Chromosomique, Pôle Couple/Enfants, CHU Grenoble, Université Grenoble Alpes, AGIM CNRS FRE3405 équipe AGC, Grenoble, France.
Fanny Morice-PicardCentre de Référence des Anomalies du Développement et Syndromes Malformatifs, CHU, Bordeaux, France.
Marie-Ange DelrueCentre de Référence des Anomalies du Développement et Syndromes Malformatifs, CHU, Bordeaux, France.
Delphine HeronUnité de Génetique Clinique, Hôpital La Pité Salpétrière, Paris, France.
Caroline RooryckLaboratoire de Génétique Moléculaire, Plateau Technique de Biologie Moléculaire, CHU, Bordeaux, France.
Alice GoldenbergCentre de Compétence des Anomalies du Développement et Syndromes Malformatifs, CHU, Rouen, France.
Pascale Saugier-VeberCentre de Compétence des Anomalies du Développement et Syndromes Malformatifs, CHU, Rouen, France.
Géraldine Joly-HélasLaboratoire de Cytologie, Cytogénétique et Biologie de la Reproduction, CHU, Rouen, France.
Patricia CalendaEEAP Tony Larue, Le Grand Quevilly, France.
Paul KuentzFHU TRANSLAD, CHU Dijon et Université de Bourgogne-Franche Comté, Dijon, France.
Sylvie Manouvrier-HanuClinique de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU, Lille, France.
Sophie Dupuis-GirodService de Génétique, Centre de Référence pour la Maladie de Rendu-Osler, Hôpital Femme-Mère-Enfant, Groupe Hospitalier Est, Bron, France.
Patrick CallierLaboratoire de Cytogénétique, Plateau Technique de Biologie, CHU, Dijon, France.
Laurence FaivreCentre de Génétique et Centre de Référence "Anomalies du Développement et Syndromes Malformatifs", Hôpital d'Enfants, CHU, Dijon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing use of array-CGH in malformation syndromes with intellectual disability could lead to the description of new contiguous gene syndrome by the analysis of the gene content of the microdeletion and reverse phenotyping. Thanks to a national and international call for collaboration by Achropuce and Decipher, we recruited four patients carrying de novo overlapping deletions of chromosome 9q33.3q34.11, including the STXBP1, the LMX1B and the ENG genes. We restrained the selection to these three genes because the effects of their haploinsufficency are well described in the literature and easily recognizable clinically. All deletions were detected by array-CGH and confirmed by FISH. The patients display common clinical features, including intellectual disability with epilepsy, owing to the presence of STXBP1 within the deletion, nail dysplasia and bone malformations, in particular patellar abnormalities attributed to LMX1B deletion, epistaxis and cutaneous-mucous telangiectasias explained by ENG haploinsufficiency and common facial dysmorphism. This systematic analysis of the genes comprised in the deletion allowed us to identify genes whose haploinsufficiency is expected to lead to disease manifestations and complications that require personalized follow-up, in particular for renal, eye, ear, vascular and neurological manifestations.

Indexed as

Chromosome DeletionAdolescentChildChromosomes, Human, Pair 9Craniofacial AbnormalitiesEndoglinEpilepsyFemaleHaploinsufficiencyHumansIntellectual DisabilityLIM-Homeodomain ProteinsMaleMunc18 ProteinsPhenotypeSyndromeEndoglinENG protein, humanLIM homeobox transcription factor 1 betaLIM-Homeodomain ProteinsMunc18 ProteinsSTXBP1 protein, humanTranscription Factors

Identifiers

PMID26395556
PMCPMC4867444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.